Merck & Co., Inc. (NYSE:MRK) Issues FY 2020 Pre-Market Earnings Guidance

Merck & Co., Inc. (NYSE:MRK) updated its FY 2020
Pre-Market earnings guidance on Friday. The company provided EPS guidance of 5.63-5.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.Merck & Co., Inc. also updated its FY20 guidance to $5.63-5.78 EPS.

Several research firms have weighed in on MRK. Wolfe Research cut Merck & Co., Inc. from an outperform rating to a peer perform rating in a report on Friday, June 12th. ValuEngine cut Merck & Co., Inc. from a hold rating to a sell rating in a research note on Monday, June 8th. Morgan Stanley restated a buy rating and issued a $89.00 target price on shares of Merck & Co., Inc. in a research note on Tuesday, June 23rd. UBS Group lowered their target price on Merck & Co., Inc. from $96.00 to $92.00 and set a buy rating for the company in a research note on Monday, April 13th. Finally, SVB Leerink lowered their target price on Merck & Co., Inc. from $98.00 to $95.00 and set an outperform rating for the company in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $94.15.

Shares of Merck & Co., Inc. stock traded up $1.25 on Friday, reaching $80.24. The company’s stock had a trading volume of 11,726,443 shares, compared to its average volume of 7,395,451. The company has a market capitalization of $202.53 billion, a price-to-earnings ratio of 20.31, a P/E/G ratio of 2.24 and a beta of 0.48. The firm’s fifty day simple moving average is $77.65 and its two-hundred day simple moving average is $79.99. Merck & Co., Inc. has a 52 week low of $65.25 and a 52 week high of $92.64. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Friday, July 31st. The company reported $1.37 EPS for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.23. The business had revenue of $10.87 billion during the quarter, compared to analyst estimates of $10.52 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The company’s quarterly revenue was down 7.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.30 EPS. As a group, research analysts predict that Merck & Co., Inc. will post 5.73 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.61 dividend. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend is Monday, September 14th. Merck & Co., Inc.’s payout ratio is 47.01%.

In related news, EVP Julie L. Gerberding sold 36,285 shares of Merck & Co., Inc. stock in a transaction on Friday, July 17th. The stock was sold at an average price of $80.00, for a total value of $2,902,800.00. Following the completion of the sale, the executive vice president now owns 62,862 shares of the company’s stock, valued at $5,028,960. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wendell P. Weeks sold 5,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $76.02, for a total value of $380,100.00. Following the completion of the sale, the director now directly owns 5,100 shares of the company’s stock, valued at approximately $387,702. The disclosure for this sale can be found here. Insiders own 0.28% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Why Invest in Dividend Kings

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.